What Is Mounjaro® (Tirzepatide)?
Mounjaro® is a prescription subcutaneous injectable medication containing tirzepatide. Unlike medications that act only on GLP-1 receptors, tirzepatide activates receptors associated with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is therefore classified as a dual GIP/GLP-1 receptor agonist.
GIP and GLP-1 are incretin hormones associated with the intestine that participate in blood glucose regulation and other metabolic processes. Through these receptor pathways, tirzepatide influences insulin secretion, glucagon regulation, appetite and satiety.
Mounjaro® is generally administered by subcutaneous injection once weekly according to a doctor’s prescription. The dosing schedule and any adjustments must be determined by individual health circumstances, medication tolerance and the applicable product information.
In Hong Kong, Mounjaro® is a prescription medication with approved indications relating to diabetes and weight management in eligible individuals. Whether a person meets the prescribing criteria must be assessed individually by a doctor, taking into account weight-related risks, medical history and applicable product information.
What Makes the Dual GIP and GLP-1 Mechanism Different?
A key characteristic of tirzepatide is its activity at two receptors associated with metabolic regulation. However, having a dual mechanism does not mean the medication is suitable for everyone, nor does it guarantee better results for every individual.
GIP: A Hormonal Signal Involved in Glucose and Metabolic Regulation
GIP is a hormone released from the intestine after food intake. It participates in blood glucose regulation by supporting insulin secretion.
Tirzepatide’s activity at GIP receptors contributes to its overall metabolic effects. However, its influence on body weight cannot be attributed to a single signalling pathway alone.
GLP-1: Appetite, Satiety and Gastric Emptying
GLP-1 is involved in insulin and glucagon secretion, gastric emptying and appetite regulation.
Through its activity at GLP-1 receptors, tirzepatide may help some individuals feel full earlier during meals and reduce their usual food intake.
The medication can also delay gastric emptying. While this contributes to certain metabolic effects, it may also be associated with nausea, bloating or other gastrointestinal symptoms.
A Dual Mechanism Does Not Replace Lifestyle Management
Even when prescription medication is used, body weight and metabolic health remain influenced by diet, physical activity, sleep, medical conditions and other medications.
Tirzepatide should therefore be considered within an appropriate medical assessment and health management plan, rather than as a complete replacement for lifestyle adjustments.
What Clinical Research Supports Mounjaro® in Weight Management?
Tirzepatide has been evaluated in several major clinical research programmes, including the SURMOUNT and SURPASS trials. These studies involved different patient populations, including adults with obesity, overweight and type 2 diabetes.
It is important to recognise that the studies differed in their medication doses, observation periods and participant characteristics. Average study results should not be interpreted as guaranteed individual outcomes.
SURMOUNT-1: Clinical Research on Changes in Body Weight
The SURMOUNT-1 trial, published in The New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity or overweight accompanied by at least one weight-related health condition. Participants with diabetes were excluded.
The study compared different once-weekly doses of tirzepatide with placebo, alongside lifestyle intervention, over a 72-week period.
Under the specified study conditions, participants receiving tirzepatide experienced greater average body weight reductions than those receiving placebo. The degree of average weight change differed between dose groups, and individual responses also varied.
These findings provide clinical evidence supporting tirzepatide for weight management in selected adults with overweight or obesity. However, they do not mean that every user will experience the same results.
SURPASS-2: Comparison with Semaglutide
The SURPASS-2 trial evaluated tirzepatide against semaglutide in patients with type 2 diabetes, examining blood glucose and body weight-related outcomes.
Within the study’s specified doses and patient population, tirzepatide demonstrated greater average improvements in certain blood glucose and body weight measures than the comparator.
However, the study used semaglutide 1 mg rather than every dose specifically investigated for weight management. Its findings therefore cannot establish that Mounjaro® is superior to all other GLP-1 medications in every clinical situation.
SURMOUNT-4: The Importance of Long-Term Weight Maintenance
The SURMOUNT-4 study, published in 2024, examined how continuing or discontinuing tirzepatide after initial weight reduction affected subsequent body weight changes.
The study found that participants who discontinued tirzepatide and switched to placebo experienced greater weight regain during the subsequent observation period. Participants who continued the medication were better able to maintain or further improve their average weight-related outcomes.
These findings highlight an important consideration: weight management involves more than short-term weight reduction. Long-term maintenance, lifestyle habits and management strategies following medication discontinuation also matter.
Does Weight Reduction Always Mean Better Metabolic Health?
Body weight and metabolic health are closely related, but they are not interchangeable.
Some individuals may experience improvements in waist circumference, blood glucose or other metabolic indicators following weight reduction. However, the extent of these changes depends on existing medical conditions, dietary habits, physical activity and other individual factors.
For this reason, medical weight management should not be evaluated solely by the number displayed on a scale.
1. Blood Glucose and Metabolic Indicators
Depending on individual needs, doctors may assess fasting blood glucose, HbA1c, blood lipids and blood pressure to understand changes in overall metabolic health.
2. Waist Circumference and Body Composition
Waist circumference can provide some information about abdominal fat distribution, while body composition assessment may help evaluate changes in fat mass and muscle mass.
Weight reduction may also involve some loss of lean body mass. Maintaining muscle function and adequate nutrition is therefore an important consideration.
3. Diet and Nutritional Status
Some individuals may reduce their usual food intake because of decreased appetite. If nutritional intake remains insufficient over time, the supply of protein and other essential nutrients may be affected.
An appropriate dietary approach should prioritise nutritional adequacy rather than simply reducing the amount of food consumed.
4. Sustainable Long-Term Health Habits
Regular physical activity, suitable resistance exercise, adequate sleep and sustainable dietary habits remain important components of overall weight management.
Who Should Receive a Comprehensive Medical Assessment Before Using Mounjaro®?
Mounjaro® is not suitable for everyone who wishes to manage their body weight. Its appropriateness depends on individual weight-related health conditions, existing illnesses, current medications and potential risks.
The following groups may require particular attention during medical assessment:
Individuals experiencing increased body weight or waist circumference alongside metabolic health concerns.
Patients with type 2 diabetes who are already using other glucose-lowering medications.
Individuals with a history of pancreatitis, gallbladder disease or significant gastrointestinal conditions.
Individuals with kidney disease or an increased risk of dehydration associated with vomiting or diarrhoea.
Individuals currently using other GLP-1 medications or prescription weight management medications.
Individuals who are pregnant, planning pregnancy or breastfeeding.
In addition, individuals with a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN 2), must pay particular attention to the contraindications stated in the applicable product information.
Doctors must also assess any other circumstances that may make the medication unsuitable. Prescribing decisions should not be based on BMI or weight changes alone.
What Side Effects and Safety Risks May Be Associated with Mounjaro®?
The most commonly reported adverse effects of Mounjaro® involve the gastrointestinal system. Some symptoms may become more noticeable when medication is first initiated or when the prescribed dose is adjusted.
Commonly reported effects include:
Nausea or vomiting
Diarrhoea or constipation
Abdominal discomfort and indigestion
Reduced appetite
Injection-site reactions
Not everyone will experience adverse effects, and their severity and duration may differ between individuals.
Important Risks That Require Additional Attention
Beyond common gastrointestinal symptoms, medical assessment should consider pancreatitis, gallbladder problems, severe gastrointestinal reactions, dehydration-related kidney problems and an increased risk of hypoglycaemia when tirzepatide is combined with certain glucose-lowering medications.
Tirzepatide may also affect gastric emptying. Individuals taking certain oral medications should therefore consult their doctor or pharmacist about whether additional precautions are necessary. Those using oral hormonal contraceptives should pay particular attention to the relevant product information.
Patients preparing for procedures involving general anaesthesia or deep sedation should also inform their medical team about their current medications.
When Should Medical Attention Be Sought?
Individuals experiencing persistent severe abdominal pain, serious allergic reactions, breathing difficulties, an inability to maintain adequate hydration or significant symptoms of hypoglycaemia should seek prompt medical attention.
Emergency medical assistance should be sought immediately if life-threatening symptoms occur.
Patients should not independently increase their dose, combine related injectable medications or abruptly change their prescribed regimen without medical assessment.
Why Is Ongoing Monitoring Important During Mounjaro® Weight Management?
Weight management is a long-term health consideration, and individuals may respond differently to prescription medication.
Even when initial weight reduction occurs, it remains important to assess nutritional intake, gastrointestinal symptoms, lifestyle factors and other health indicators.
Ongoing monitoring allows doctors to review individual responses and determine whether adjustments to the broader management approach may be necessary.
Before Starting: Understanding Individual Health Status
An initial assessment may include body weight, BMI, waist circumference, personal and family medical history, current medications and relevant metabolic indicators.
The need for additional laboratory investigations or other assessments should be determined according to individual medical risks.
During Use: Monitoring Physical Responses and Nutrition
Regular follow-up may include changes in body weight and waist circumference, dietary intake, adverse effects, medication tolerance and, where appropriate, blood glucose or other health indicators.
If food intake decreases significantly, nutritional adequacy and physical functioning should also be considered.
Long-Term Management: Looking Beyond Initial Weight Loss
Clinical research indicates that some individuals may experience weight regain after discontinuing related medications.
Before deciding whether to continue, adjust or stop medication, patients should discuss an appropriate plan with their doctor and establish sustainable dietary, physical activity and health management habits.
How Does BMS Clinic Support Personalised Medical Weight Management?
BMS Clinic emphasises medical assessment, personalised planning and ongoing health monitoring rather than treating body weight as the sole measure of success.
When considering Mounjaro® or other medical weight management options, doctors review individual health circumstances, current physical conditions and relevant risks to help patients understand the suitability and limitations of different approaches.
Areas of assessment may include:
Initial Medical Consultation: Reviewing medical history, body weight changes, current medications and individual health management goals.
Metabolic Health Assessment: Evaluating blood glucose, blood pressure, waist circumference and other relevant health indicators where appropriate.
Medication Suitability Assessment: Considering approved indications, contraindications, potential adverse effects and drug interactions.
Lifestyle Management: Discussing diet, physical activity, sleep and everyday health habits.
Ongoing Health Monitoring: Arranging appropriate follow-up appointments and reviewing management strategies according to individual responses and needs.
All prescribing decisions must be made by a doctor based on the patient’s health circumstances and applicable product information. No single medication should be regarded as a standard solution suitable for everyone.
Key Takeaways
Tirzepatide, the active ingredient in Mounjaro®, acts through dual GIP and GLP-1 receptor mechanisms involved in blood glucose, appetite and body weight regulation.
Major clinical studies support its use in selected patient populations. However, individual responses, medication tolerance and long-term management requirements may differ.
For people considering medical weight management, the key considerations extend beyond short-term changes in body weight. Metabolic health, nutritional status, medication safety and sustainable maintenance strategies are equally important.
Through medical assessment and ongoing health monitoring, individuals can develop a clearer understanding of whether a prescription approach is appropriate and how to establish a health management plan suited to their circumstances.
Frequently Asked Questions
Is Mounjaro® suitable for everyone seeking weight management?
Mounjaro® is not suitable for everyone. Doctors must consider BMI, weight-related health conditions, personal and family medical history, current medications and relevant contraindications. Even when weight reduction is desired, an appropriate medical assessment should be conducted first.
How does Mounjaro® differ from other GLP-1 medications?
Tirzepatide, the active ingredient in Mounjaro®, acts on both GIP and GLP-1 receptors, whereas some other medications primarily act on GLP-1 receptors. Approved indications, dosing arrangements, clinical evidence and safety considerations may differ. These medications should not be switched independently.
How often is Mounjaro® generally administered?
Mounjaro® is generally administered by subcutaneous injection once weekly according to a doctor's prescription. The injection schedule, dose and any adjustments should follow medical instructions and the applicable product information. Patients should not independently increase their prescribed dose.
Can weight return after stopping Mounjaro®?
Some individuals may experience weight regain after discontinuing the medication. Clinical studies have also observed weight regain following tirzepatide withdrawal. Individual responses vary, and patients should discuss long-term weight maintenance, dietary habits, physical activity and follow-up management with their doctor.
Is regular monitoring necessary while using Mounjaro®?
Appropriate medical follow-up is important. Depending on individual circumstances, doctors may monitor body weight, waist circumference, blood glucose and other metabolic indicators, while also reviewing appetite, nutritional intake and possible adverse effects. The type and frequency of monitoring should be determined according to individual needs.
References
1. Medication Information and Hong Kong Regulatory Sources
- The Government of the Hong Kong Special Administrative Region. LCQ12: Combating the Illegal Sale of Controlled Anti-obesity Drugs. 2026.
- Hong Kong Department of Health, Drug Office. Mounjaro KwikPen Solution for Injection in Pre-filled Pen 7.5mg/0.6ml. Registration No. HK-68413.
2. Dual Receptor Mechanisms and Glycaemic Control Research
3. Clinical Research on Weight Management
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26–36. doi:10.1056/NEJMoa2416394.
4. Long-Term Weight Maintenance and Metabolic Health
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945.
- Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392:958–971. doi:10.1056/NEJMoa2410819.